STX2 and hemolytic-uremic syndrome: We designed a double-blind, placebo-controlled, adaptive, phase 2/3 study to evaluate the pharmacokinetics, safety, and efficacy of INM004 in pediatric patients with Stx2-positive bloody diarrhea for the prevention of HUS.